The Current and Future States of Screening in Gynecologic Cancers


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2020.
        CA Cancer J Clin. 2020; 70: 7-30
        • Rahib L.
        • Smith B.D.
        • Aizenberg R.
        • et al.
        Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States.
        Cancer Res. 2014; 74: 2913-2921
        • Bokhman J.V.
        Two pathogenetic types of endometrial carcinoma.
        Gynecol Oncol. 1983; 15: 10-17
        • Ueda S.M.
        • Kapp D.S.
        • Cheung M.K.
        • et al.
        Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths.
        Am J Obstet Gynecol. 2008; 198: 218.e1-6
        • National Comprehensive Cancer Network
        Uterine neoplasms (Version 2.2020).
        (Available at:) (Accessed September 22, 2020)
        • Soliman P.T.
        • Bassett R.L.
        • Wilson E.B.
        • et al.
        Limited public knowledge of obesity and endometrial cancer risk: what women know.
        Obstet Gynecol. 2008; 112: 835-842
        • Washington C.R.
        • Haggerty A.
        • Ronner W.
        • et al.
        Knowledge of endometrial cancer risk factors in a general gynecologic population.
        Gynecol Oncol. 2020; 158: 137-142
        • Zhang K.
        • Luo Y.
        • Dai H.
        • et al.
        Effects of Bariatric Surgery on Cancer Risk: Evidence from Meta-analysis.
        Obes Surg. 2020; 30: 1265-1272
        • Jareid M.
        • Thalabard J.-C.
        • Aarflot M.
        • et al.
        Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.
        Gynecol Oncol. 2018; 149: 127-132
        • Derbyshire A.E.
        • Allen J.L.
        • Gittins M.
        • et al.
        PROgesterone Therapy for Endometrial Cancer prevention in obese women (PROTEC) trial: a feasibility study.
        Cancer Prev Res. 2020;
        • Allen N.E.
        • Key T.J.
        • Dossus L.
        • et al.
        Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC).
        Endocr Relat Cancer. 2008; 15: 485-497
        • Crosbie E.J.
        • Zwahlen M.
        • Kitchener H.C.
        • et al.
        Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis.
        Cancer Epidemiol Biomarkers Prev. 2010; 19: 3119-3130
        • Arnold M.
        • Pandeya N.
        • Byrnes G.
        • et al.
        Global burden of cancer attributable to high body-mass index in 2012: a population-based study.
        Lancet Oncol. 2015; 16: 36-46
        • Shaw E.
        • Farris M.
        • McNeil J.
        • et al.
        Obesity and Endometrial Cancer.
        Recent Results Cancer Res. 2016; 208: 107-136
        • Barry J.A.
        • Azizia M.M.
        • Hardiman P.J.
        Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis.
        Hum Reprod Update. 2014; 20: 748-758
        • Fisher B.
        • Costantino J.P.
        • Redmond C.K.
        • et al.
        Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.
        J Natl Cancer Inst. 1994; 86: 527-537
        • National Comprehensive Cancer Network
        Genetic/Familial High-Risk Assessment: Colorectal (Version 1.2021).
        (Available at:) (Accessed September 22, 2020)
        • Cote M.L.
        • Ruterbusch J.J.
        • Olson S.H.
        • et al.
        The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women.
        Cancer Epidemiol Biomarkers Prev. 2015; 24: 1407-1415
        • Doll K.M.
        • Khor S.
        • Odem-Davis K.
        • et al.
        Role of bleeding recognition and evaluation in Black-White disparities in endometrial cancer.
        Am J Obstet Gynecol. 2018; 219: 593.e1-14
        • Romano S.S.
        • Doll K.M.
        The Impact of Fibroids and Histologic Subtype on the Performance of US Clinical Guidelines for the Diagnosis of Endometrial Cancer among Black Women.
        Ethn Dis. 2020; 30: 543-552
      1. Ries LAG, Young JL, Keel GE, et al (editors). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics.
        (Available at:) (Accessed December 24, 2020)
        • Clarke M.A.
        • Long B.J.
        • Del Mar Morillo A.
        • et al.
        Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis.
        JAMA Intern Med. 2018; 178: 1210-1222
        • Gerber B.
        • Krause A.
        • Müller H.
        • et al.
        Ultrasonographic detection of asymptomatic endometrial cancer in postmenopausal patients offers no prognostic advantage over symptomatic disease discovered by uterine bleeding.
        Eur J Cancer. 2001; 37: 64-71
      2. ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol 2018;131(5):e124-e129.

        • Fung M.F.K.
        • Reid A.
        • Faught W.
        • et al.
        Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen.
        Gynecol Oncol. 2003; 91: 154-159
        • Lu K.H.
        • Loose D.S.
        • Yates M.S.
        • et al.
        Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome.
        Cancer Prev Res Phila Pa. 2013; 6: 774-781
        • Jemal A.
        • Ward E.M.
        • Johnson C.J.
        • et al.
        Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival.
        J Natl Cancer Inst. 2017; 109
        • Njoku K.
        • Chiasserini D.
        • Jones E.R.
        • et al.
        Urinary Biomarkers and Their Potential for the Non-Invasive Detection of Endometrial Cancer.
        Front Oncol. 2020; 10: 559016
        • Bakkum-Gamez J.N.
        • Wentzensen N.
        • Maurer M.J.
        • et al.
        Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.
        Gynecol Oncol. 2015; 137: 14-22
        • Calis P.
        • Yuce K.
        • Basaran D.
        • et al.
        Assessment of Cervicovaginal Cancer Antigen 125 Levels: A Preliminary Study for Endometrial Cancer Screening.
        Gynecol Obstet Invest. 2016; 81: 518-522
        • Heng S.
        • Stephens A.N.
        • Jobling T.W.
        • et al.
        Measuring PC activity in endocervical swab may provide a simple and non-invasive method to detect endometrial cancer in post-menopausal women.
        Oncotarget. 2016; 7: 46573-46578
        • Kinde I.
        • Bettegowda C.
        • Wang Y.
        • et al.
        Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
        Sci Transl Med. 2013; 5: 167ra4
        • Wang Y.
        • Li L.
        • Douville C.
        • et al.
        Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers.
        Sci Transl Med. 2018; 10
        • Nair N.
        • Camacho-Vanegas O.
        • Rykunov D.
        • et al.
        Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study.
        PLoS Med. 2016; 13: e1002206
        • Ferlay J.
        • Soerjomataram I.
        • Dikshit R.
        • et al.
        Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
        Int J Cancer. 2015; 136: E359-E386
        • Norquist B.M.
        • Harrell M.I.
        • Brady M.F.
        • et al.
        Inherited Mutations in Women With Ovarian Carcinoma.
        JAMA Oncol. 2016; 2: 482-490
        • Pal T.
        • Permuth-Wey J.
        • Betts J.A.
        • et al.
        BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
        Cancer. 2005; 104: 2807-2816
        • Kuchenbaecker K.B.
        • Hopper J.L.
        • Barnes D.R.
        • et al.
        Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
        JAMA. 2017; 317: 2402-2416
        • US Preventive Services Task Force
        • Grossman D.C.
        • Curry S.J.
        • et al.
        Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement.
        JAMA. 2018; 319: 588-594
        • Buys S.S.
        • Partridge E.
        • Black A.
        • et al.
        Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
        JAMA. 2011; 305: 2295-2303
        • Jacobs I.J.
        • Menon U.
        • Ryan A.
        • et al.
        Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
        Lancet. 2016; 387: 945-956
        • National Comprehensive Cancer Network
        Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 1.2021).
        (Available at:) (Accessed September 22, 2020)
        • Kauff N.D.
        • Domchek S.M.
        • Friebel T.M.
        • et al.
        Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study.
        J Clin Oncol. 2008; 26: 1331-1337
        • Finch A.P.M.
        • Lubinski J.
        • Møller P.
        • et al.
        Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
        J Clin Oncol. 2014; 32: 1547-1553
        • Rosenthal A.N.
        • Fraser L.S.M.
        • Philpott S.
        • et al.
        Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
        J Clin Oncol. 2017; 35: 1411-1420
        • Skates S.J.
        • Greene M.H.
        • Buys S.S.
        • et al.
        Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
        Clin Cancer Res. 2017; 23: 3628-3637
        • Moore R.G.
        • Miller M.C.
        • Disilvestro P.
        • et al.
        Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass.
        Obstet Gynecol. 2011; 118: 280-288
        • Gentry-Maharaj A.
        • Blyuss O.
        • Ryan A.
        • et al.
        Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women.
        Cancers. 2020; 12
        • Pearl M.L.
        • Zhao Q.
        • Yang J.
        • et al.
        Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer.
        Gynecol Oncol. 2014; 134: 581-590
        • Zhang X.
        • Li H.
        • Yu X.
        • et al.
        Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker.
        Cell Physiol Biochem. 2018; 48: 1983-1994
        • Vanderstichele A.
        • Busschaert P.
        • Smeets D.
        • et al.
        Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses.
        Clin Cancer Res. 2017; 23: 2223-2231
        • Pereira E.
        • Camacho-Vanegas O.
        • Anand S.
        • et al.
        Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
        PLoS One. 2015; 10: e0145754
        • Kurman R.J.
        • Shih I.-M.
        Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.
        Hum Pathol. 2011; 42: 918-931
        • Pramanik S.
        • Yang E.
        • Wu W.
        Cytologic studies of in vivo fallopian tube specimens in patients undergoing salpingo-oophorectomy.
        CytoJournal. 2020; 17: 19
        • Chen H.
        • Klein R.
        • Arnold S.
        • et al.
        Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection.
        J Vis Exp Jove. 2017; 125
        • Ersoy E.
        • Kashikar R.M.
        Psammoma bodies in Papanicolaou tests and associated factors to predict an underlying malignancy: a clinicopathological analysis of 10 cases.
        J Am Soc Cytopathol. 2020; 9: 266-271
        • Wu T.-I.
        • Huang R.-L.
        • Su P.-H.
        • et al.
        Ovarian cancer detection by DNA methylation in cervical scrapings.
        Clin Epigenetics. 2019; 11: 166
        • Saslow D.
        • Solomon D.
        • Lawson H.W.
        • et al.
        American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer.
        Am J Clin Pathol. 2012; 137: 516-542
        • Schiffman M.
        • Castle P.E.
        • Jeronimo J.
        • et al.
        Human papillomavirus and cervical cancer.
        Lancet. 2007; 370: 890-907
        • Muñoz N.
        Human papillomavirus and cancer: the epidemiological evidence.
        J Clin Virol. 2000; 19: 1-5
        • Szymonowicz K.A.
        • Chen J.
        Biological and clinical aspects of HPV-related cancers.
        Cancer Biol Med. 2020; 17: 864-878
        • de Sanjose S.
        • Quint W.G.
        • Alemany L.
        • et al.
        Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
        Lancet Oncol. 2010; 11: 1048-1056
        • Papanicolaou G.N.
        Science. 1942; 95: 438-439
        • Perkins R.B.
        • Guido R.S.
        • Castle P.E.
        • et al.
        2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.
        J Low Genit Tract Dis. 2020; 24: 102-131
        • Gattoc L.
        • Nair N.
        • Ault K.
        Human Papillomavirus Vaccination.
        Obstet Gynecol Clin North Am. 2013; 40: 177-197
        • Fontham E.T.H.
        • Wolf A.M.D.
        • Church T.R.
        • et al.
        Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.
        CA Cancer J Clin. 2020; 70: 321-346
        • Liu G.
        • Sharma M.
        • Tan N.
        • et al.
        HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer.
        AIDS. 2018; 32: 795-808
      3. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.
        (Available at:) (Accessed December 20, 2020)
        • Moscicki A.-B.
        • Flowers L.
        • Huchko M.J.
        • et al.
        Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.
        J Low Genit Tract Dis. 2019; 23: 87-101
        • Cheung L.C.
        • Egemen D.
        • Chen X.
        • et al.
        2019 ASCCP Risk-Based Management Consensus Guidelines: Methods for Risk Estimation, Recommended Management, and Validation.
        J Low Genit Tract Dis. 2020; 24: 90-101
        • Egemen D.
        • Cheung L.C.
        • Chen X.
        • et al.
        Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines.
        J Low Genit Tract Dis. 2020; 24: 132-143
        • Demarco M.
        • Egemen D.
        • Raine-Bennett T.R.
        • et al.
        A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines.
        J Low Genit Tract Dis. 2020; 24: 144-147
        • Snijders P.J.F.
        • Verhoef V.M.J.
        • Arbyn M.
        • et al.
        High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening.
        Int J Cancer. 2013; 132: 2223-2236
        • Tranberg M.
        • Jensen J.S.
        • Bech B.H.
        • et al.
        Urine collection in cervical cancer screening - analytical comparison of two HPV DNA assays.
        BMC Infect Dis. 2020; 20: 926
        • Cho H.-W.
        • Ouh Y.-T.
        • Hong J.H.
        • et al.
        Comparison of urine, self-collected vaginal swab, and cervical swab samples for detecting human papillomavirus (HPV) with Roche Cobas HPV, Anyplex II HPV, and RealTime HR-S HPV assay.
        J Virol Methods. 2019; 269: 77-82
      4. Lichter K, Krause D, Xu J, et al. Adjuvant HPV vaccination with surgical excision to prevent recurrent CIN2+: A systematic review and meta-analysis. Featured Poster Session presented at the: Society of Gynecologic Oncology Annual Meeting; March 2020.

      5. Lei J, Ploner A, Elfström KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med 2020;383(14):1340-1348.

        • Liverani C.A.
        • Di Giuseppe J.
        • Giannella L.
        • et al.
        Cervical Cancer Screening Guidelines in the Postvaccination Era: Review of the Literature.
        J Oncol. 2020; 2020: 8887672
        • Hacker N.F.
        • Eifel P.J.
        • van der Velden J.
        Cancer of the vagina.
        Int J Gynaecol Obstet. 2015; 131: S84-S87
        • Khadraoui H.
        • Thappa S.
        • Smith M.
        • et al.
        Age-associated trends of vulvar cancer in the US.
        Menopause N Y N. 2020;
        • Alkatout I.
        • Schubert M.
        • Garbrecht N.
        • et al.
        Vulvar cancer: epidemiology, clinical presentation, and management options.
        Int J Womens Health. 2015; 7: 305-313
        • American Cancer Society
        Cancer Facts & Figures 2020.
        Atlanta Am Cancer Soc, 2020
      6. Committee on Gynecologic Practice of American College Obstetricians and Gynecologists. ACOG Committee Opinion No. 509: Management of vulvar intraepithelial neoplasia.
        Obstet Gynecol. 2011; 118: 1192-1194
        • US Preventive Services Task Force
        • Bibbins-Domingo K.
        • Grossman D.C.
        • et al.
        Screening for Gynecologic Conditions With Pelvic Examination: US Preventive Services Task Force Recommendation Statement.
        JAMA. 2017; 317: 947
        • Qaseem A.
        • Humphrey L.L.
        • Harris R.
        • et al.
        Clinical Guidelines Committee of the American College of Physicians. Screening pelvic examination in adult women: a clinical practice guideline from the American College of Physicians.
        Ann Intern Med. 2014; 161: 67-72
        • American Academy of Family Physicians
        Summary of Recommendations for Clinical Preventive Services.
        (Available at:) (Accessed December 24, 2020)
        • Conry J.A.
        • Brown H.
        Well-Woman Task Force: Components of the Well-Woman Visit.
        Obstet Gynecol. 2015; 126: 697-701
      7. ACOG Committee Opinion No. 755 Summary: Well-Woman Visit.
        Obstet Gynecol. 2018; 132: 1084-1085
        • U.S. Food & Drug Administration
        Nucleic Acid Based Tests.
        (Available at:) (Accessed December 29, 2020)
        • Salazar K.L.
        • Duhon D.J.
        • Olsen R.
        • et al.
        A review of the FDA-approved molecular testing platforms for human papillomavirus.
        J Am Soc Cytopathol. 2019; 8: 284-292